secwatch.observer — SEC 8-K summary
======================================

Issuer:     BillionToOne, Inc. (BLLN)
CIK:        0002070849
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001628280-25-056077
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BillionToOne Q3 revenue $83.5M (+117% YoY); guides FY2025 revenue $293-299M
---------------------------------------------------------------------------

- Q3 total revenue $83.5M (+117% YoY); prenatal revenue $74.1M (+102%), oncology $8.7M (7.6x YoY).
- GAAP operating income of $9.6M vs. ($12.6M) loss YoY; net income $1.5M ($0.10 diluted EPS).
- Gross margin improved to 70% from 53% YoY; tests delivered up 52% to 165,000; ASP up 44% to $501.
- Guides FY2025 revenue $293-299M (93-96% growth); expects positive operating income for Q4 and full year.
- Appointed Anthony Pagano (Genmab CFO) as Audit Committee Chair, effective Jan 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2070849/000162828025056077/0001628280-25-056077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2070849/000162828025056077/blln-20251209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-056077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer